Medwell Capital welcomes new CFO

    




 EDMONTON, March 26, 2012 /CNW/ - Medwell Capital Corp.  today  announced the appointment of Tami Reich, CMA, to the position of Chief  Financial Officer. Ms. Reich will take over from Brent Johnston as CFO  on April 2, 2012. 

 Ms. Reich was most recently the Chief Operating Officer at BAMM Ventures  Inc. (BAMM), an Edmonton-based venture capital firm where she oversaw a  staff of over 60 people and offices throughout Alberta. Over the course  of her career, she has also founded and operated two separate  accounting firms focused on advising small to mid-sized businesses. 

 "We are pleased to welcome Tami to the Medwell team as we advance our  portfolio of late stage healthcare investments and search for  undervalued opportunities in the sector," said Kevin Giese, President  and CEO of Medwell. "Her experience in a venture capital setting and  her entrepreneurial background bring a valuable body of knowledge to  our group. Brent fulfilled the CFO role at Medwell during an important  period of transition. We thank him sincerely for the time he has been  with us and for his support." 

 Brent Johnston joined Medwell Capital as CFO in 2008 and was active in  guiding the Company through its evolution into a diversified investment  and advisory firm. He is leaving to pursue other opportunities. 

 About Medwell Capital Corp. 

 Medwell Capital Corp. is a Canadian-based investment and and advisory  firm. For further information please visit www.medwellcapital.com. 

 Neither TSX Venture Exchange nor its Regulation Services Provider (as  that term is defined in the policies of the TSX Venture Exchange)  accepts responsibility for the adequacy or accuracy of this release.   This press release may contain forward-looking statements, which  reflect the Company's current expectation regarding future events.   These forward-looking statements involve risks and uncertainties that  may cause actual results, events or developments to be materially  different from any future results, events or developments expressed or  implied by such forward-looking statements.  Such factors include, but  are not limited to, changing market conditions, the successful and  timely completion of clinical studies, the establishment of corporate  alliances, the impact of competitive products and pricing, new product  development, uncertainties related to the regulatory approval process  and other risks detailed from time to time in the Corporation's ongoing  quarterly and annual reporting.  We undertake no obligation to publicly  update or revise any forward-looking statements, whether as a result of  new information, future events or otherwise. 

Medwell Capital Corp.


CONTACT:  Tony HesbyMedwell Capital Corp.780-413-7152780-408-3040 FaxE-mail: [e-mail]: http://www.medwellcapital.comRoss MarshallInvestor Relations416-815-0700 ext. 238416-815-0080 FaxE-mail:[e-mail] 


    

Copyright